Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
BNT162b2 mRNA Covid-19 Vaccine
BIOLOGICAL
2 trials
Sponsors
University of Roma La Sapienza
, Ente Ospedaliero Ospedali Galliera
Conditions
Cancer, Treatment-Related
Covid-19
Neoplasms
Unknown Phase
Antibodies Response to mRNA Vaccine Against Covid-19
NCT04733807
University of Roma La Sapienza
Covid-19
Start: 2021-01-28
End: 2022-02-01
Target: 600
Updated: 2021-05-11
BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment
Completed
NCT04932863
Ente Ospedaliero Ospedali Galliera
Cancer, Treatment-Related, Neoplasms
Start: 2021-03-15
End: 2023-03-15
Updated: 2025-08-08
Related Papers
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
European Journal of Cancer
2021-10-11
46 citations